Multiple analyses in clinical trials: Sound science or data dredging?

Medical Journal of Australia

Volumn 181, Issue 8, 2004, Pages 452-454

  Lord, Sarah J ^a   Gebski, Val J ^a   Keech, Anthony C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PRAVASTATIN;

ANALYTICAL ERROR; ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COVARIANCE; DATA ANALYSIS; DRUG ELUTING STENT; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL PARAMETERS; OUTCOMES RESEARCH; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 7044224928     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06376.x     Document Type: Article

References (17)

1. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials 1997; 18: 530-545.
2. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977; 198: 679-684.
3. Cook DI, Gebski VJ, Keech AC. Subgroup analysis in clinical trials. Med J Aust 2004; 180: 289-291. www.mja.com.au/public/issues/180_06_150304/coo10086_fm.html
4. Simes RJ, Gebski VJ, Keech AC. Subgroup analysis: application to individual patient decisions. Med J Aust 2004; 180: 467-469. www.mja.com.au/public/issues/180_09_030504/sim10218_fm.html
5. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-2465.
6. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
7. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial. J Clin Oncol 2003; 21: 588-592.
8. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
9. Stone GWM, Ellis SGM, Cox DAM, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947.
10. Beller EM, Gebski V, Keech AC. Randomisation in clinical trials. Med J Aust 2002; 177: 565-567. www.mja.com.au/public/issues/177_10_181102/bel10697_fm.html
11. White H. and Hirulog and Early Reperfusion or Occlusion (HERO) Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-1863.
12. Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J 2000; 139: 745-751.
13. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21: 2917-2930.
14. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-1069.
15. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998; 19: 604-621.
16. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102: 2329-2334.
17. O'Connor FF, Shields DC, Fitzgerald A, et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256-3260.